Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients

Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage a...

Full description

Bibliographic Details
Main Authors:	Beltammer Belkais, Gargoom Ali, Taeib Ghada, Duweb Gamal
Format:	Article
Language:	English
Published:	Sciendo 2019-03-01
Series:	Serbian Journal of Dermatology and Venereology
Subjects:	psoriasis ustekinumab dermatologic agents biological therapy treatment outcome libya
Online Access:	https://doi.org/10.2478/sjdv-2019-0002

id	doaj-74069b33f7c9439cbdd896c958e4f948
record_format	Article
spelling	doaj-74069b33f7c9439cbdd896c958e4f9482021-09-05T14:01:55ZengSciendoSerbian Journal of Dermatology and Venereology1821-09022406-06312019-03-01111131810.2478/sjdv-2019-0002sjdv-2019-0002Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris PatientsBeltammer Belkais0Gargoom Ali1Taeib Ghada2Duweb Gamal3Dermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaDermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaDermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaDermatology Department, Faculty of Medicine, Benghazi University, Benghazi-LibyaIntroduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage activation and release of various cytokins, such as interleukin 12 (IL-12) and IL-23. Recently a new biologic agent Ustekinumab has been used in the treatment of psoriasis. Our aim in this study was to assess the efficacy and tolerability of ustekinumab in moderate to severe psoriasis vulgaris and to observe and report any adverse reaction.https://doi.org/10.2478/sjdv-2019-0002psoriasisustekinumabdermatologic agentsbiological therapytreatment outcomelibya
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Beltammer Belkais Gargoom Ali Taeib Ghada Duweb Gamal
spellingShingle	Beltammer Belkais Gargoom Ali Taeib Ghada Duweb Gamal Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients Serbian Journal of Dermatology and Venereology psoriasis ustekinumab dermatologic agents biological therapy treatment outcome libya
author_facet	Beltammer Belkais Gargoom Ali Taeib Ghada Duweb Gamal
author_sort	Beltammer Belkais
title	Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
title_short	Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
title_full	Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
title_fullStr	Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
title_full_unstemmed	Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients
title_sort	use of ustekinumab in the treatment of libyan psoriasis vulgaris patients
publisher	Sciendo
series	Serbian Journal of Dermatology and Venereology
issn	1821-0902 2406-0631
publishDate	2019-03-01
description	Introduction. Psoriasis is a relatively common chronic inflammatory disease. It clinically manifests as raised, well defined erythematous plaques with irregular borders and silvery scales. Psoriasis appears to be mediated by abnormal immune system functioning, including T lymphocyte and macrophage activation and release of various cytokins, such as interleukin 12 (IL-12) and IL-23. Recently a new biologic agent Ustekinumab has been used in the treatment of psoriasis. Our aim in this study was to assess the efficacy and tolerability of ustekinumab in moderate to severe psoriasis vulgaris and to observe and report any adverse reaction.
topic	psoriasis ustekinumab dermatologic agents biological therapy treatment outcome libya
url	https://doi.org/10.2478/sjdv-2019-0002
work_keys_str_mv	AT beltammerbelkais useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients AT gargoomali useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients AT taeibghada useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients AT duwebgamal useofustekinumabinthetreatmentoflibyanpsoriasisvulgarispatients
_version_	1717809399480713216

Use of Ustekinumab in the Treatment of Libyan Psoriasis Vulgaris Patients

Similar Items